Blindness Warning Hits Popular GLP-1 drugs

A rare eye disease is now written into the safety label of one of the most popular weight-loss drugs on the planet.

Story Snapshot

European and British regulators now list NAION, a sudden-blindness eye condition, as a very rare side effect of semaglutide drugs like Wegovy, Ozempic, and Rybelsus.
The European Medicines Agency (EMA) says users face roughly double the risk of this eye condition compared to non-users, though the overall chance stays low.
An Indiana woman’s public account of losing sight in one eye after starting a GLP-1 drug has fueled renewed attention and lawsuits.
Novo Nordisk, the maker of Wegovy and Ozempic, denies any proven causal link and says the drugs’ benefits still outweigh the risks.

Regulators In Europe And Britain Move First

The EMA’s safety committee spent months digging through clinical trials, lab studies, and real-world reports before reaching its conclusion in June 2025. The verdict: NAION, short for nonarteritic anterior ischemic optic neuropathy, counts as a very rare side effect of semaglutide. Regulators told Novo Nordisk to update its product information across Europe, covering diabetes, weight-loss, and heart-risk uses alike.

NAION damages the optic nerve when blood flow gets cut off suddenly. It often strikes without warning and can cause permanent vision loss in one eye. The EMA said users with type 2 diabetes taking semaglutide face about twice the risk of developing it compared to those who don’t take the drug. Regulators also said treatment should stop right away if a patient is confirmed to have the condition.

Britain Follows With Its Own Warning

The United Kingdom’s health regulator added its own alert in early 2026, naming Wegovy, Ozempic, and Rybelsus directly. The notice described NAION as “very rarely reported” among people using semaglutide for diabetes, weight management, or heart-risk reduction. That warning brings Britain in line with the European stance, even though the two reviews ran on separate timelines and slightly different evidence.

A study published in JAMA Ophthalmology backs up the regulatory concern. Researchers tracked nearly 17,000 patients and found a higher rate of NAION among those prescribed semaglutide compared to people on other diabetes or obesity drugs. Separately, a review of the Food and Drug Administration’s adverse event database found a strong reporting signal tied almost entirely to semaglutide, out of 96 total eye-injury cases examined.

A Patient’s Story Puts A Face On The Numbers

Statistics rarely stick with readers the way a personal story does. An Indiana woman named Elizabeth Wild Gessner told a local news crew she started a GLP-1 drug in spring 2024 and lost sight in her right eye that September. Doctors diagnosed NAION. She later had trouble in her other eye and stopped the medication.

Her account doesn’t prove causation on its own, and no court has ruled on her case. But it mirrors the pattern regulators flagged: sudden one-eye vision loss showing up months after starting the drug. That timing detail matters, since several studies suggest the risk concentrates in the first year or two of treatment rather than spreading evenly over time.

Novo Nordisk Pushes Back Hard

The drugmaker isn’t conceding the point. Novo Nordisk says its own internal safety reviews, plus outside academic studies, show no change in semaglutide’s risk profile. The company insists no causal relationship has been proven between its drugs and NAION, and points to blinded ophthalmologist reviews from its clinical trials that turned up very few confirmed cases.

That denial deserves weight, not dismissal. Regulators themselves describe the risk as low in absolute terms, and much of the evidence comes from observational studies that can be muddied by the fact that diabetic and obese patients already carry higher baseline odds of eye trouble. Common sense says something can be true and still get exaggerated once lawyers and cable news get involved, and more than 3,000 lawsuits are now pending against GLP-1 makers over side effects.

What This Means For Patients Weighing The Tradeoff

None of this settles whether semaglutide truly causes blindness in a given person, and it likely never will with total certainty. What’s settled is that two respected regulatory bodies, working independently, looked at the data and decided patients deserve a warning on the label. That’s a reasonable, conservative standard: when in doubt, tell people the risk exists and let them decide with their doctor.

Patients on Wegovy, Ozempic, or Rybelsus should know the warning signs of sudden vision change and report them immediately. The drugs still carry real benefits for weight and heart health, and one added case per roughly 10,000 patient-years isn’t a reason for panic. It is, however, a reason for informed consent, not corporate reassurance alone.